<i>In Vitro</i> Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection
Mariana Albano, Melissa J. Karau, Kerryl E. Greenwood‐Quaintance, Douglas R. Osmon, Caitlin P. Oravec, Daniel J. Berry, Matthew P. Abdel, Robin Patel
Antimicrobial Agents and Chemotherapy · 2019-08
Abstract
The in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high.
MeSH terms
- Rifabutin
- Microbiology
- Rifapentine
- Rifamycin
- Rifaximin
- Staphylococcus epidermidis
- Antibiotics
- Rifampicin
- Antibacterial agent
- Biology
- Staphylococcus aureus
- Medicine